Subscribe to RSS
DOI: 10.1055/a-1382-9983
Estradiol-Responsive miR-365a-3p Interacts with Tissue Factor 3′UTR to Modulate Tissue Factor-Initiated Thrombin Generation
Funding This study was supported by Murdoch University Small Grants and Perth Blood Institute.

Abstract
Background High estradiol (E2) levels are linked to an increased risk of venous thromboembolism; however, the underlying molecular mechanism(s) remain poorly understood. We previously identified an E2-responsive microRNA (miR), miR-494–3p, that downregulates protein S expression, and posited additional coagulation factors, such as tissue factor, may be regulated in a similar manner via miRs.
Objectives To evaluate the coagulation capacity of cohorts with high physiological E2, and to further characterize novel E2-responsive miR and miR regulation on tissue factor in E2-related hypercoagulability.
Methods Ceveron Alpha thrombin generation assay (TGA) was used to assess plasma coagulation profile of three cohorts. The effect of physiological levels of E2, 10 nM, on miR expression in HuH-7 cells was compared using NanoString nCounter and validated with independent assays. The effect of tissue factor-interacting miR was confirmed by dual-luciferase reporter assays, immunoblotting, flow cytometry, biochemistry assays, and TGA.
Results Plasma samples from pregnant women and women on the contraceptive pill were confirmed to be hypercoagulable (compared with sex-matched controls). At equivalent and high physiological levels of E2, miR-365a-3p displayed concordant E2 downregulation in two independent miR quantification platforms, and tissue factor protein was upregulated by E2 treatment. Direct interaction between miR-365a-3p and F3-3′UTR was confirmed and overexpression of miR-365a-3p led to a decrease of (1) tissue factor mRNA transcripts, (2) protein levels, (3) activity, and (4) tissue factor-initiated thrombin generation.
Conclusion miR-365a-3p is a novel tissue factor regulator. High E2 concentrations induce a hypercoagulable state via a miR network specific for coagulation factors.
Author Contributions
J.T.: Drafted and edited the manuscript, performed the experiments, and analyzed the data. M.J.A.: Conceptualized, evaluated the data, edited and revised the manuscript. J.W.T.T.: Conceptualized, drafted the method sections of the manuscript, performed the experiments, and analyzed the data. I.J.: Performed statistical analyses on NanoString nCounter data and evaluated the data. S.P.: Performed the experiments and evaluated the data. Q.W.H.: Conceptualized, evaluated the data, and edited the manuscript. G.G.: Performed the experiments and evaluated the data. R.I.B.: Conceptualized, evaluated the data, and edited the manuscript. J.Y-H.T.: Conceptualized the experiments, evaluated the data, edited and revised the manuscript.
* Current affiliation: PathWest Laboratory Medicine, WA, Australia.
Publication History
Received: 14 July 2020
Accepted: 02 February 2021
Accepted Manuscript online:
04 February 2021
Article published online:
22 April 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany